Related Experiment Videos
[Ciliary body changes associate with aldose reductase in galactosemic rats (2)]
H Ikebe1, H Terubayashi, S Okamoto
1Department of Ophthalmology, Kyoto Prefectural University of Medicine, Japan.
Nippon Ganka Gakkai Zasshi
|July 1, 1992
Summary
Aldose reductase inhibition prevents ciliary body non-pigmented epithelial cell hypertrophy in galactosemic rats. This suggests aldose reductase plays a role in diabetic eye complications.
Area of Science:
- Ophthalmology
- Diabetic Complications Research
- Cell Biology
Context:
- Diabetic retinopathy is a leading cause of vision loss.
- The ciliary body epithelium is implicated in diabetic ocular pathologies.
- Galactosemia models are used to study diabetic complications.
Purpose:
- To investigate the role of aldose reductase in ciliary body epithelium changes.
- To assess the effect of aldose reductase inhibitor (FR74366) on galactose-induced hypertrophy.
- To determine if aldose reductase is a therapeutic target for diabetic eye disease.
Summary:
- Rats fed a 50% galactose diet for 18 months exhibited hypertrophy of the non-pigmented ciliary body epithelium.
- Treatment with aldose reductase inhibitor FR74366 prevented this observed hypertrophy.
- Morphometric analysis confirmed structural changes were specific to non-pigmented epithelial cells.
Impact:
- Provides evidence linking aldose reductase activity to ciliary body hypertrophy in a diabetic model.
- Suggests aldose reductase inhibitors may be a viable therapeutic strategy for managing diabetic eye complications.
- Highlights the non-pigmented ciliary epithelium as a potential site for aldose reductase-mediated damage in diabetes.